Navigation Links
New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals of Internal Medicine has published the results of a two-year clinical study on the impact of genistein on bone loss. The paper, "Effects of the Phytoestrogen Genistein on Bone Metabolism in Osteopenic Postmenopausal Women-A Randomized Trial," appears in the current issue (June 19, 2007) and details the safety and efficacy of genistein for the dietary management of osteopenia and osteoporosis. The paper reports a significant gain in bone density among patients taking genistein at both 12 and 24 months over both baseline and placebo.

Key study findings include:

-- Over 85 percent of the women in the study taking genistein showed a gain in bone density.

-- Patients taking genistein in addition to calcium and vitamin D showed a gain in bone density of approximately 3 percent per year over baseline and 6 percent per year over those taking the placebo.

-- No adverse events were reported in the study. All participants were monitored for vasomotor symptoms, vaginal bleeding, breast tenderness, endometrial thickness, depression, irritability, insomnia, and gastrointestinal (GI) symptoms, as well as for changes in hematologic, renal and liver function tests. No changes were noted in any of these parameters except for mild GI symptoms.

Patients in the test group of the study used 54 mg/day of highly purified genistein isolated from soy along with calcium and vitamin D. Principle Investigator for the study, Francesco Squadrito, M.D., Professor of Pharmacology and Head of Clinical Pharmacology, School of Medicine, University of Messina, Italy, explains that there were some interesting aspects to the study: "The placebo in this study was not an inactive pill; instead it was the current standard of care for osteopenia - calcium plus vitamin D. Unlike other research in this area, this study was controlled for soy intake and additional supplem
'"/>




Page: 1 2 3

Related medicine technology :

1. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
2. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
3. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
4. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
5. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
6. POZEN Announces Positive Outcome for PA 325 Proof of Concept Study
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:8/19/2014)... -- ChemImage founder and CTO, Patrick J. Treado ... innovative diagnostic procedure for the detection of colorectal cancer ... (SPEC) conference in Krakow, Poland . ... in vitro Diagnostics for Detection of Colorectal Cancer Using ... poster session on Tuesday, August 19, 2014 from 6:30 ...
(Date:8/19/2014)... 19, 2014 Research and Markets has ... of Material, by Technology, by Application & by Region- Global ... The demand for membranes is estimated to ... market to $29.31 billion Membrane technology was first ... as water filtration and kidney dialysis. In modern times, membranes ...
(Date:8/19/2014)... MAHWAH, N.J. , Aug. 19, 2014  Stryker Corporation,s ... TOUR and Champions Tour, is bringing its message of joint ... New Jersey this week at The Barclays.  ... will be in the Spectator Village near the 17 th ... Paramus starting on Thursday, August 21 st . ...
Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5
... Oct. 19, 2009 Amylin Pharmaceuticals, Inc. (Nasdaq: ... obesity program will be presented at Obesity 2009, the ... be held in Washington, D.C. October 24-28. Phase 2 ... be the subject of a late-breaking oral presentation. Obesity ...
... , SILVER SPRING, Md., Oct. 19 The U.S. Food ... to be approved for kidney cancer since 2005. , (Logo: ... oral medication that interferes with angiogenesis, the growth of new ... , Votrient is intended for people with advanced renal ...
Cached Medicine Technology:Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 2Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 3Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 4Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 5FDA Approves New Treatment for Advanced Form of Kidney Cancer 2
(Date:8/20/2014)... According to a new market research report ... Crystal, Microblinds, Thermographic and Photochromics), by application (Architectural, ... geography - Global Forecast to 2014 - 2020", ... market was worth $1581.4 Million in 2013, and ... at an estimated CAGR of 20% from 2014 ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... leading nonprofit authority on the use of health ... announced the full agenda for its annual fall ... IT Efficiency. WEDI-Con 2014 will take place at ... 20-23, 2014, attracting a diverse cross-section of payers, ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running ... starting blocks. , Urbini, a new collection of versatile baby ... Avi jogger to its lineup. , The Avi has ... inspired by the latest racing styles and a set of ... jogger offers a swift, smooth ride on runs, power-walks and ...
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... clinic has found a cure for it. With extensive research ... Therapy provider named ‘MetroMD’ claims to have perfected the art ... give you a brand new younger look with their revolutionary ... the secrets of the 21st century fountain of youth, the ...
(Date:8/20/2014)... Doctors at the University of Hong Kong claim to ... mice by injecting them with a vaccine that changes their ... on its website. Click here to read the full ... Institute of Microbiology created a vaccine using a protein called ... the vaccine is designed to prevent mesothelioma cells from disabling ...
Breaking Medicine News(10 mins):Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2
... permission with European medicine regulators to begin selling its new ... in the US last month, and comes slightly earlier than ... be one of GSK's most promising pipeline drugs as well ... the sales of the drug could cross 2 bln used ...
... world who get uncomfortable after a heavy meal here is ... have proven that eating 6-8 walnuts (approx.40g) after a rich ... triggered of in the walls of arteries after a highly ... the Oct. 17 issue of the Journal of the American ...
... given to bowel cancer patients before the surgical removal ... risk of recurrence to 1 %. The usual ... of recurrence is there and once reappeared, treatment is ... conducted an international study, to compare the effect of ...
... after irrigation water samples tested positive for E. coli ... relaxed its advisory against eating fresh spinach. ... detected after a secondary water source temporarily used to ... the water got contaminated is still not clear. ...
... challenges parenting stereotypes; Today’s parents boast about the numerous classes ... and the many talents they possess. Competitive parents in their ... ‘super-kids’ , often smother their children with an over-dose of ... gizmos , play stations, and game boys… and Oh boy, ...
... Around 45 Iraqi children have arrived in Bahrain to receive ... to arrive in the coming days as part of an ... move Sunday came in response to a call to help ... composer Naseer Shamma, who is the head of the newly ...
Cached Medicine News:Health News:Walnuts May Help Fight Fat and Keep Arteries Supple 2
... if it is not the Flu? Streptococcus ... bacterial "flu-like" infections. The easy-to-use, rapid, urine-based ... within the new 4 hour guidelines. Rapid ... improved patient outcomes and lower overall health ...
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Single Use Loading Units (SULU's) Knifeless for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Single Use Loading Units (SULU's) with Titanium Staples for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Medicine Products: